OK-432 as a Sclerosing Agent to Treat Wound-Healing Impairment

Abstract

We report on the application of OK-432 (picibanil) in a patient with prolonged wound healing impairment. A 13-year-old girl had suffered a polytrauma with a displaced fracture of the sacrum which required neurosurgical decompression of the sacral plexus. Postoperatively, a seroma with recurrent fistulation was seen. Excision of the wound, prolonged suction drainage and the instillation of hypertonic glucose solution did not have any effect over a period of four months postoperatively. Relying on our personal experience of the treatment of lymphangiomas using OK-432 we instilled OK-432 into the wound. Leakage stopped immediately, there was a regression of fluid accumulation and four weeks later the ultrasound examination was normal. The patient is still asymptomatic four years after treatment. OK-432 can be used effectively for the treatment of chronic wound healing impairment.

Key words

picibanil - OK‐432 - wound healing - seroma

References

• 1 Fujino A, Moriya Y, Morikawa Y, Hoshino K, Watanabe T, Shimojima N, Kitajima M. A role of cytokines in OK‐432 injection therapy for cystic lymphangioma: an approach to the mechanism.  J Pediatr Surg. 2003;  38 1806-1809
• 2 Giguère C M, Baumann N M, Sato Y, Burke D K, Greinwald J H, Pransky S, Kelley P, Georgeson K, Smith R JH. Treatment of lymphangiomas with OK‐432 (picibanil) sclerotherapy. A prospective multi-institutional trial.  Arch Otolaryngol Head Neck Surg. 2002;  128 1137-1144
• 3 Luzzatto C, Lo Piccolo R, Fascetti Leon F, Zanon G F, Toffolutti T, Tregnaghi A. Further experience with OK‐432 for lymphangiomas.  Pediatr Surg Int. 2005;  21 969-972
• 4 Ogita S, Tsuto T, Tokiwa K, Takahashi T. Intracystic injection of OK‐432: a new sclerosing therapy for cystic hygroma in children.  Br J Surg. 1987;  74 690-691
• 5 Ogita S, Tsuto T, Nakamura K, Deguchi E, Iwai N. OK‐432 therapy in 64 patients with lymphangioma.  J Pediatr Surg. 1994;  29 784-785
• 6 Ogita S, Tsuto T, Nakamura K, Deguchi E, Tokiwa K, Iwai N. OK‐432 therapy for lymphangioma in children: why and how does it work?.  J Pediatr Surg. 1996;  31 477-480
• 7 Schmidt B, Schimpl G, Höllwarth M E. OK 432 therapy of lymphangiomas in children.  Eur J Pediatr. 1996;  155 649-652
• 8 Torisu M, Katano M, Kimura Y, Itoh H, Takesue M. New approach to malignant ascites with a streptococcal preparation, OK‐432. I. Improvement of host immunity and prolongation of survival.  Surgery. 1983;  93 357-364
• 9 Uchida A, Micksche M. Intrapleural administration of OK‐432 in cancer patients: activation of NK cells and reduction of suppressor cells.  Int J Cancer. 1983;  31 1-5